AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
Log in

OTCMKTS:STDAFSTADA Arzneimittel Stock Price, Forecast & News

$78.85
0.00 (0.00 %)
(As of 06/4/2020 12:26 PM ET)
Add
Compare
Today's Range
$78.85
Now: $78.85
$78.85
50-Day Range
$75.04
MA: $77.29
$78.85
52-Week Range
$75.15
Now: $78.85
$105.00
VolumeN/A
Average Volume0 shs
Market Capitalization$4.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.5
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Omeprazol for gastric ulcer/reflux. The Branded Products segment offers APO-Go for Parkinson's disease; Grippostad for cold; Aqualor for rhinitis/soare throat; Snup for rhinitis; and Vitaprost for prostate disease. It serves doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, and wholesalers or mail-order companies. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH.
Read More
STADA Arzneimittel logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:STDAF
Previous SymbolNASDAQ:STDAF
CUSIPN/A
CIKN/A
Phone49-6101-6030

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.75 billion
Cash Flow$8.20 per share
Book Value$22.32 per share

Profitability

Miscellaneous

Employees10,416
Market Cap$4.92 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter.

STADA Arzneimittel (OTCMKTS:STDAF) Frequently Asked Questions

How has STADA Arzneimittel's stock been impacted by COVID-19 (Coronavirus)?

STADA Arzneimittel's stock was trading at $88.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STDAF shares have decreased by 11.3% and is now trading at $78.85. View which stocks have been most impacted by Coronavirus.

Has STADA Arzneimittel been receiving favorable news coverage?

News headlines about STDAF stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. STADA Arzneimittel earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutSTADA Arzneimittel.

Who are some of STADA Arzneimittel's key competitors?

Who are STADA Arzneimittel's key executives?

STADA Arzneimittel's management team includes the following people:
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 62)
  • Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 55)
  • Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 54)
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 44)
  • Ms. Kay Reubelt, Director of Investor Relations

What is STADA Arzneimittel's stock symbol?

STADA Arzneimittel trades on the OTCMKTS under the ticker symbol "STDAF."

How do I buy shares of STADA Arzneimittel?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is STADA Arzneimittel's stock price today?

One share of STDAF stock can currently be purchased for approximately $78.85.

How big of a company is STADA Arzneimittel?

STADA Arzneimittel has a market capitalization of $4.92 billion and generates $2.75 billion in revenue each year. STADA Arzneimittel employs 10,416 workers across the globe.

What is STADA Arzneimittel's official website?

The official website for STADA Arzneimittel is www.stada.com.

How can I contact STADA Arzneimittel?

STADA Arzneimittel's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.